Filing Details
- Accession Number:
- 0001140361-14-044349
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-12-05 18:59:01
- Reporting Period:
- 2014-12-05
- Filing Date:
- 2014-12-05
- Accepted Time:
- 2014-12-05 18:59:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1302573 | Oncomed Pharmaceuticals Inc | OMED | Pharmaceutical Preparations (2834) | 383572512 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1297000 | Denise Pollard-Knight | C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-12-05 | 24,245 | $21.58 | 2,019,264 | No | 4 | S | Indirect | See Footnote |
Common Stock | Disposition | 2014-12-05 | 755 | $22.10 | 2,018,509 | No | 4 | S | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See Footnote |
No | 4 | S | Indirect | See Footnote |
Footnotes
- This transaction was executed in multiple trades in prices ranging from $21.05 to $22.03, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares of common stock of OMED are owned by Phase4 Ventures III LP ("Phase4"). The Reporting Person is a partner of Phase4 Partners Limited, which is the manager of Phase4. The Reporting Person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein.